Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Antibodies, Monoclonal, Humanized
/ administration & dosage
Area Under Curve
Biological Products
/ administration & dosage
Clinical Trials, Phase III as Topic
Dose-Response Relationship, Drug
Drug Administration Schedule
Etanercept
/ administration & dosage
Female
Humans
Infliximab
/ administration & dosage
Male
Network Meta-Analysis
Patient Selection
Prognosis
Psoriasis
/ diagnosis
Randomized Controlled Trials as Topic
Risk Assessment
Severity of Illness Index
Treatment Outcome
United States
Ustekinumab
/ administration & dosage
area under the curve
biologics
cumulative benefit
ixekizumab
meta-analysis
psoriasis
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
01
11
2018
revised:
06
12
2019
accepted:
19
12
2019
pubmed:
31
12
2019
medline:
25
11
2020
entrez:
30
12
2019
Statut:
ppublish
Résumé
Cumulative clinical improvement and speed of improvement are important to psoriasis patients. Compare cumulative benefits of biologics over 12 to 16 weeks in the treatment of moderate to severe psoriasis. A systematic literature review identified phase III trial data on Psoriasis Area and Severity Index (PASI) responses for biologics during 12 and 16 weeks of treatment. Cumulative clinical benefit, measured by the area under the curve for PASI ≥75% improvement (PASI 75), ≥90% improvement (PASI 90), and 100% improvement (PASI 100), was compared using the network meta-analysis and Bayesian methodology on the relative probability of achieving percentage of maximum area under the curve. Among biologics approved for psoriasis treatment, anti-interleukin-17 biologics demonstrated consistently greater cumulative clinical benefits on PASI 75, PASI 90, and PASI 100 over the 12- or 16-week period than anti-interleukin-23 and other biologics. For biologics with 12-week data, ixekizumab and brodalumab showed greater cumulative benefits for PASI 75, PASI 90, and PASI 100 than secukinumab, followed by guselkumab, infliximab, adalimumab, ustekinumab, and etanercept. Ixekizumab showed greater cumulative benefits than all other biologics reporting 16-week data. Recently approved biologics were not included. Ixekizumab (at 12 weeks and 16 weeks) and brodalumab (at 12 weeks) had greater cumulative clinical benefit than all of other biologics studied.
Sections du résumé
BACKGROUND
BACKGROUND
Cumulative clinical improvement and speed of improvement are important to psoriasis patients.
OBJECTIVE
OBJECTIVE
Compare cumulative benefits of biologics over 12 to 16 weeks in the treatment of moderate to severe psoriasis.
METHODS
METHODS
A systematic literature review identified phase III trial data on Psoriasis Area and Severity Index (PASI) responses for biologics during 12 and 16 weeks of treatment. Cumulative clinical benefit, measured by the area under the curve for PASI ≥75% improvement (PASI 75), ≥90% improvement (PASI 90), and 100% improvement (PASI 100), was compared using the network meta-analysis and Bayesian methodology on the relative probability of achieving percentage of maximum area under the curve.
RESULTS
RESULTS
Among biologics approved for psoriasis treatment, anti-interleukin-17 biologics demonstrated consistently greater cumulative clinical benefits on PASI 75, PASI 90, and PASI 100 over the 12- or 16-week period than anti-interleukin-23 and other biologics. For biologics with 12-week data, ixekizumab and brodalumab showed greater cumulative benefits for PASI 75, PASI 90, and PASI 100 than secukinumab, followed by guselkumab, infliximab, adalimumab, ustekinumab, and etanercept. Ixekizumab showed greater cumulative benefits than all other biologics reporting 16-week data.
LIMITATIONS
CONCLUSIONS
Recently approved biologics were not included.
CONCLUSION
CONCLUSIONS
Ixekizumab (at 12 weeks and 16 weeks) and brodalumab (at 12 weeks) had greater cumulative clinical benefit than all of other biologics studied.
Identifiants
pubmed: 31884091
pii: S0190-9622(19)33315-8
doi: 10.1016/j.jaad.2019.12.038
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biological Products
0
guselkumab
089658A12D
brodalumab
6ZA31Y954Z
Infliximab
B72HH48FLU
ixekizumab
BTY153760O
Ustekinumab
FU77B4U5Z0
Etanercept
OP401G7OJC
Types de publication
Comparative Study
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1138-1149Informations de copyright
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.